Tolerance induced via TLR2 and TLR4 in human dendritic cells: role of IRAK-1 by Albrecht, Valerie et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
BMC Immunology
Open Access Research article
Tolerance induced via TLR2 and TLR4 in human dendritic cells: role 
of IRAK-1
Valerie Albrecht1, Thomas PJ Hofer1, Brian Foxwell2, Marion Frankenberger1 
and Loems Ziegler-Heitbrock*1
Address: 1Helmholtz Center München, German Research Center for Environmental Health and Asklepios-Fachkliniken Gauting, Clinical 
Cooperation Group, Inflammatory Lung Diseases, 82131 Gauting, Germany and 2Imperial College, The Kennedy Institute for Rheumatology, 
London, UK
Email: Valerie Albrecht - valerie.albrecht@med.uni-muenchen.de; Thomas PJ Hofer - hofer@helmholtz-muenchen.de; 
Brian Foxwell - b.foxwell@ic.ac.uk; Marion Frankenberger - frankenberger@helmholtz-muenchen.de; Loems Ziegler-Heitbrock* - ziegler-
heitbrock@helmholtz-muenchen.de
* Corresponding author    
Abstract
Background: While dendritic cells (DCs) can induce tolerance in T cells, little is known about
tolerance induction in DCs themselves. We have analysed tolerance induced in human in-vitro
generated DCs by repeated stimulation with ligands for TLR4 and TLR2.
Results: DCs stimulated with the TLR4 ligand LPS did show a rapid and pronounced expression
of TNF mRNA and protein. When DCs were pre-cultured for 2 days with 5 ng LPS/ml then the
subsequent response to stimulation with a high dose of LPS (500 ng/ml) was strongly reduced for
both TNF mRNA and protein. At the promoter level there was a reduced transactivation by the -
1173 bp TNF promoter and by a construct with a tetrameric NF-B motif. Within the signalling
cascade leading to NF-B activation we found an ablation of the IRAK-1 adaptor protein in LPS-
tolerant DCs. Pre-culture of DCs with the TLR2 ligand Pam3Cys also led to tolerance with respect
to TNF gene expression and IRAK-1 protein was ablated in such tolerant cells as well, while IRAK-
4 protein levels were unchanged.
Conclusion: These data show that TLR-ligands can render DCs tolerant with respect to TNF gene
expression by a mechanism that likely involves blockade of signal transduction at the level of IRAK-
1.
Background
Tolerance of immune cells will occur when leukocytes
down-regulate their response after a primary encounter
with antigen or other ligands. Tolerance can act via dele-
tion, receptor down-regulation, blockade of signal trans-
duction or via the action of suppressive cytokines.
Monocytes and dendritic cells (DCs) belong to the innate
immune system but they are instrumental in instructing
the cells of the adaptive immune system via antigen pres-
entation and cytokine production. One of the main
cytokines produced by these cells is tumor necrosis factor
(TNF), a cytokine that acts at various levels in order to pro-
mote immune response and inflammation.
TNF is produced upon activation of monocytes and DCs
by microbial products like lipopolysaccharide (LPS) of
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Pam3Cys, which act by binding to toll like receptors
(TLRs). When cells are exposed to these compounds
repeatedly, then the TNF production is decreased, i.e. the
cells have become tolerant. The molecular mechanism of
tolerance to date has been studied only in monocytes and
macrophages. For LPS stimulation it was shown early on
that the CD14 co-receptor was not down but rather up-
regulated in tolerant cells [1]. Also, signal transduction
still occurred with mobilisation of p50/p65 of NF-B, but
there was at the same time an increase in NF-B p50-
homodimers which bind to the promoter and displace the
p50/p65 heterodimer. Since p50 cannot transactivate this
will lead to blockade of TNF gene expression [1,2]. In
addition to this p50-homodimer mechanism, blockade in
LPS tolerant monocytes can also occur through interrup-
tion of the signalling cascade at the level of IRAK-1 in that
this adaptor protein is proteolytically degraded [3,4]. For
monocytes tolerant to the TLR-ligand Pam3Cys this mech-
anism also applied and there was a strong and complete
ablation of IRAK-1 [5].
Different mechanisms of tolerance operate in different
cell types in that in lymphocytes deletion of cells is a
major mechanism, while in monocytes blockade of signal
transduction predominates. Because of this tissue specifi-
city in tolerance mechanisms we have induced and ana-
lysed tolerance in mature human DCs.
When looking at tolerance induction in DCs Karp et al. [6]
and demonstrated that pre-culture with a low dose of LPS
led to a 80% reduction of IL-12 protein production upon
secondary stimulation with a high dose of LPS. Other than
that little is known about tolerance in mature DCs after
TLR-ligation and the molecular mechanisms have not
been studied. We show herein that tolerance can be
induced in dendritic cells both with TLR2 and TLR4 lig-
ands and that the mechanism involved is the ablation of
the adaptor molecule IRAK-1. Such tolerance of DCs,
which is characterised by lack of proper production of
TNF and IL-12, will contribute to reduced immune
responses in clinical settings like sepsis.
Results
Generation of DCs and induction of TNF
We generated DCs by culturing of PBMC for 5 days with
GM-CSF and IL-13 followed by further culturing for 2
days with addition of PGE2. The cell surface phenotype of
DCs was determined by flow cytometry and as shown in
Fig. 1 the cells generated in this way exhibit a high level
expression of CD1a, CD209 and CD83. In average of 9
experiments there were 48.4+/- 20.7% positive cells for
CD1a, 39.9 +/- 14.5% positive cells for CD83 and 89.5 +/
- 8.1% positive cells for CD209. These data demonstrate
that the cells generated are mature DCs.
We then studied expression of the TNF gene in these day
7 DCs after stimulation with highly purified LPS from Sal-
monella abortus equi. We can show in dose response analy-
sis a 40-fold induction already at a LPS dose of 0.1 ng/ml
with an 80-fold induction at 1 – 1000 ng/ml (Fig. 2A).
Time course analysis revealed an early peak at 2 hours
post addition of LPS with only 10% of the maximum level
left at 8 hours and a return to the unstimulated level at 24
hours (Fig. 2B).
Induction of LPS tolerance in DCs
We then used these mature day 7 DCs and pre-cultured
them for another 2 days without or with LPS at 5 ng/ml.
When cells were left untreated during the preculture
Cell surface phenotype of monocyte-derived dendritic cells Figure 1
Cell surface phenotype of monocyte-derived dendritic cells. Adherent mononuclear cells were cultured for 7 days 
with GM-CSF and IL-13 with addition of PGE2 for the final 2 days. Cells were then stained with specific monoclonal antibodies 
or the respective isotype controls and analysed in flow cytometry. Percentage of positive cells for CD1a were 48.4 ± 20.7%, 
for CD83 39.9 ± 14.5% and for CD209 89.5 ± 8.1%. Shown is one representative of 9 experiments.
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Dose response and time course analysis for LPS induced TNF mRNA in monocyte-derived DCs Figure 2
Dose response and time course analysis for LPS induced TNF mRNA in monocyte-derived DCs. A. Day 7 den-
dritic cells were stimulated with different doses of LPS from Salmonella abortus equi and after 2 hours TNF mRNA levels were 
determined by RT-PCR. All mRNA levels were adjusted to - Enolase as house keeping gene. TNF mRNA expression was 
then calculated in AU while setting the value for TNF levels in unstimulated cells as one. Given is mean of 3 experiments. * = p 
< 0.05 compared to w/o. B. Dendritic cells were stimulated for different times with 500 ng/ml of LPS from Salmonella abortus 
equi and TNF mRNA levels were determined by RT-PCR. The maximum TNF mRNA expression level at 2 hours was set as 
100%. Adjustment to - Enolase was done as mentioned for Fig. 2A. Given is mean of 3 experiments. * = p < 0.05 compared to 
0 h.
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period and then stimulated with LPS at 500 ng/ml on day
9 then we could observe a 205-fold induction of TNF
mRNA (Fig. 3A, average of n = 7). Cells pre-cultured with
LPS at 5 ng/ml and stimulated on day 9 at 500 ng/ml
responded with a much lower TNF mRNA expression,
which was only 8-fold (Fig. 3A).
The same pattern was seen when testing 6 h supernatants
for TNF protein. Here naïve cells stimulated with LPS pro-
duced an average of 15 000 pg TNF/ml, which is a greater
1000-fold stimulation compared to 9 pg/ml in unstimu-
lated cells (Fig. 3B). Tolerant DCs stimulated with LPS
only produced 900 pg TNF/ml reflecting a 3-fold induc-
tion compared to unstimulated tolerant cells (Fig. 3B).
These data demonstrate an almost complete blockade of
TNF gene expression in LPS-tolerant DCs.
Since DCs were generated from blood monocytes isolated
by adherence there were still some contaminating lym-
phocytes remaining at day 7 of culture. In order to dem-
onstrate that DCs were in fact the responder cells in this
system we isolated CD83+ cells by MACS separation to
greater 90% purity and subjected them to LPS pre-culture
followed by LPS stimulation. As shown in Fig. 3C the
purified CD83+ DCs gave the same pattern of response
with a pronounced induction of TNF mRNA in the naïve
cells and no response in cells pre-cultured with LPS.
Promoter activity and signal transduction in LPS tolerance 
in DC
Expression of the TNF gene is to a large extent governed by
its promoter. In order to analyse whether LPS tolerance in
DCs operates at the promoter level we infected DCs with
an adenovirus containing the human -1173 bp TNF pro-
moter up-stream of the luciferase reportergene. This was
done one day into the pre-culture without or with LPS and
after culture with the virus overnight cells were stimulated
with LPS and luciferase activity was measured. Figure 4A
demonstrates a strong induction of the promoter by LPS
in naïve cells (in average 83.3 -fold). DCs made tolerant
by pre-culture with LPS showed only a 12.0-fold increase
in promoter activity (Fig. 4A).
One of the crucial transcription factors that control the
TNF gene is NF-B [7-10]. We therefore asked whether LPS
tolerance in DCs is regulated by this transcription factor.
For this we infected DCs with an adenovirus containing 4
copies of a NF-B binding motif upstream of the luciferase
reporter gene and analysed the response to tolerance
induction. As shown in Fig. 4B the NF-B dependent luci-
ferase was strongly induced in naïve cells (in average 96.8
-fold) and this was down to only 20.4 -fold in LPS tolerant
cells. Taken together, these data show that LPS tolerance
in human DCs operates at the level of the TNF promoter
and is crucially dependent on NF-B.
LPS is a prototypic stimulus of monocytes and in these
cells it acts via CD14, MD2 and TLR4 cell surface receptors
with TLR4 transmitting the signal into the cells by engag-
ing molecules like MyD88 and TRIF. The MyD88 pathway
involves recruitment of IRAK-1, which initiates a signal-
ling cascade that leads to activation of IKKs and these will
phosphorylate I-B. I-B is degraded and allows for NF-B
to be released and to go into the nucleus and transactivate
genes like TNF. Blockade of signal transduction has been
reported to occur at various levels in LPS tolerance and
here the predominant mechanisms are a) up-regulation of
p50 homodimers and b) ablation of IRAK-1 [1-4]. In pre-
liminary experiments we could not detect an increase in
p50 homodimers in tolerant DC (not shown). Therefore,
we have asked whether tolerance to LPS in DCs may be
due to blockade at the level of IRAK-1. As shown by West-
ern blotting IRAK-1 is clearly detectable in naïve DCs but
after induction of tolerance it is strongly reduced (Fig.
5A). In average of 4 experiments LPS tolerant cells (pre-
treated without additional stimulation, lane 3 Fig. 5A)
showed IRAK-1 at a level of 20.5 +/- 7.7% of the naïve
cells (p < 0.05). Under the same conditions SHIP protein
did not show any change with the tolerant cells giving
only a slightly higher expression level of the protein (Fig.
5B, 3 versus 1: 157.2% +/- 98.8). These data suggest that
LPS tolerance in human DCs acts by interrupting signal
transduction at the level of IRAK-1.
LPS tolerance leads to blockade of IL-12 expression
IL-12 is another prominent cytokine in DCs and it is also
controlled by the transcription factor NF-B. We therefore
have asked whether LPS tolerant DCs will also down-reg-
ulate IL-12p40. RT-PCR analysis of lysates taken after 6 hs
of stimulation of naïve cells did show a 50-fold induction
of IL-12p40 mRNA (Fig. 6). By contrast, DCs pre-cultured
with a low dose of LPS followed by stimulation with a
high dose of LPS did not show any induction of IL-12
mRNA anymore. Looking at CD80 and CD86 no signifi-
cantly different expression was seen in tolerant cells. Also,
expression of IL-10 was inducible by LPS in naïve den-
dritic cells and inducibility was maintained in tolerant
cells (data not shown).
Pam3Cys Tolerance in DCs
Tolerance in monocytes can be induced via LPS targeting
TLR4 and via Pam3Cys targeting TLR2. We have analysed
TNF expression in human DCs pre-treated without or with
Pam3Cys for 2 days at 1 g/ml followed by stimulation
with Pam3Cys at 10 g/ml. As shown in Figure 7A, toler-
ance was readily induced as naïve cells showed a 19.6 -
fold induction of TNF mRNA while pre-treated cells
exhibited only a 1.9-fold induction.
When we probed cellular extracts from such cells for
IRAK-1 then we found again a pronounced depletion ofBMC Immunology 2008, 9:69 http://www.biomedcentral.com/1471-2172/9/69
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Figure 3 (see legend on next page)
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IRAK-1 protein in Pam3Cys pre-treated cells (Fig. 7B).
Here Pam3Cys stimulation for 1 h led already to an almost
complete depletion of IRAK-1 protein and this continued
to be low in Pam3Cys tolerant cells on day 2 (lane 3). In
average of 3 experiments the IRAK-1 protein level in toler-
ant cells on day 2 was 1.2 +/- 0.3% as determined by den-
sitometry. At the same time IRAK-4 protein levels
remained unchanged (Fig. 7C).
Discussion
Tolerance is a principle mechanism in biology and
describes the absence of a response after repeated stimula-
tion of a cell. Tolerance in the immune system can operate
via deletion of reactive cells, receptor downregulation,
blockade of signalling and suppression via cytokines. TLR-
ligand induced tolerance in monocytes/macrophages has
been studied extensively and blockade of signal transduc-
tion appears to be the main mechanism of tolerance in
these cells. Here blockade has been demonstrated to oper-
ate at various levels along the signalling cascade and this
includes failure of MyD88 to be recruited to TLR4 [11],
up-regulation of IRAK-M [12] or SHIP [13], up-regulation
of suppressor of cytokine signalling-1 [14,15] and down-
regulation of MAP-kinases [16].
A major mechanism of tolerance that can be demon-
strated in macrophages but also in T cells and tumor cells
is the up-regulation of p50 mRNA and increased translo-
cation of p50-homodimers into the nucleus [1,17-
19,2,20-22]. More recently the proteolytic degradation of
IRAK-1 has been shown to represent another major mech-
anism [4,3,23-25]. In a study on cells that were generated
over 5 days in the presence of IL-4, GM-CSF and LPS, a
reduced TNF production was noted when compared to
cells generated with IL-4 and GM-CSF only [26]. The cells
generated with LPS did, however, fail to express the DCs
marker CD83 and it appears that TNF production was
compared between 2 different types of DCs rather then in
mature DCs that were pre-cultured without and with LPS.
For mature dendritic cells TLR-mediated tolerance has
been addressed only in 2 reports [6,27] and for human
DCs a down-regulation of IL-12 protein was demon-
strated when cells, pre-cultured with a low dose of LPS,
were stimulated with a high dose of LPS [6]. The molecu-
lar mechanism of tolerance in these cells has, however,
not been studied.
We have analysed tolerance to TLR-ligands in the human
system and for this have generated monocyte-derived DCs
via 7 day culture with GM-CSF, IL-13 and PGE2. PGE2 was
used in the final 2 days in order to induce DCs to a mature
stage. We have used this step deliberately since matura-
tion with standard signals like LPS or TNF may induce tol-
erance on their own. The cells generated in our study were
clearly DCs based on their expression of CD1a, CD83 and
DC-SIGN. Stimulation of such cells was done with LPS
from S. abortus equi, which was highly purified LPS to
remove any contaminant lipoprotein such that TLR4 but
not TLR2 was targeted. This LPS induced a rapid produc-
tion of TNF mRNA which was still high at 1 ng/ml with a
decreased response at 0.1 ng/ml. For induction of toler-
ance to LPS we used a low dose of LPS (5 ng/ml) and after
pre-culture for 2 days stimulated with a high dose of 500
ng/ml, i.e. a 100-fold higher dose. The low dose still was
capable to almost completely block the TNF production
by the high dose of LPS, thus demonstrating the efficiency
of blockade. There was, however, some residual TNF
expression in the tolerant cells and this has also been seen
in previous studies with tolerant monocytes/macrophages
[4,18,1]. This blockade of TNF production in the present
study was clearly due to mechanisms operating in DCs
since it could be equally demonstrated in purified CD83+
cells (Fig. 3A and 3C).
When addressing the molecular mechanism of this LPS
tolerance we initially looked at the activity of the human
TNF promoter and of NF-B restricted reporter constructs.
Since DCs are difficult to transfect with standard proce-
dures, we have used adenoviral promoter luciferase
reporter constructs for this purpose. These studies demon-
Induction of LPS tolerance in dendritic cells Figure 3 (see previous page)
Induction of LPS tolerance in dendritic cells.A. Induction of LPS tolerance in dendritic cell cultures at the level of TNF 
mRNA at day 7 dendritic cells were cultured for additional 2 days with LPS at 5 ng/ml and then washed and stimulated at 500 
ng LPS/ml. Cells were lysed at 2 hours and RNA was extracted, transcribed into cDNA and amplified by RT-PCR and data 
were normalized relative to levels of the house keeping gene alpha-Enolase. Given is the average of 7 experiments. * = p < 0.05 
compared to 0/LPS. B. Induction of LPS tolerance in dendritic cell cultures at the level of TNF protein. Day 7 dendritic cells 
were cultured for additional 2 days with LPS at 5 ng/ml and then washed and stimulated at 500 ng LPS/ml for 6 hours. Superna-
tants were then harvested and were tested for TNF protein by ELISA. Given is the average of 3 experiments. * = p < 0.05 com-
pared to 0/LPS. C. Induction of LPS tolerance in CD83+ dendritic cells at the level of TNF mRNA. Day 7 CD83+ dendritic cells 
were isolated by MACS to > 90% purity and these cells were then cultured for additional 2 days with LPS at 5 ng/ml, washed 
and stimulated at 500 ng LPS/ml. Cells were lysed and RNA was extracted, transcribed into cDNA and amplified by RT-PCR 
and data were normalized relative to levels of the house keeping gene alpha-Enolase. Given is the average of 3 experiments. * 
= p < 0.05 compared to 0/LPS.BMC Immunology 2008, 9:69 http://www.biomedcentral.com/1471-2172/9/69
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Figure 4 (see legend on next page)
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strated a reduced TNF promoter activity in tolerant cells
and this is similar to what has been shown in LPS tolerant
monocytes [1,2]. This suggested that the blockade is at or
up-stream of the transcription level. The finding of down-
regulation of a construct carrying 4-NF-B motifs further-
more suggested that the NF-B signalling pathway might
be involved. In preliminary gelshift analysis (data not
shown) we found no consistent increase of p50-
homodimers but rather a failure of NF-B p50p65 to be
mobilised into the nucleus. We therefore went on to study
upstream elements by Western blotting. In these studies
we found no change in the expression of the SHIP protein
(Fig. 5B) but IRAK-1 protein was strongly depleted in LPS
tolerant cells (Fig. 5A). Since IRAK-1 is an essential adap-
tor protein in the signalling cascade, leading from the TLR
receptor structure to mobilisation of NF-B, this depletion
of IRAK-1 explains the tolerance of DCs. When looking at
tolerance induction after ligation of TLR-2 we also found
a strong down-regulation of TNF mRNA and IRAK-1 was
also completely ablated by this treatment. The effect of
A. Reduced TNF promoter activity in LPS tolerant dendritic cells Figure 4 (see previous page)
A. Reduced TNF promoter activity in LPS tolerant dendritic cells. Day 7 dendritic cells were pre-cultured without 
and with LPS at 5 ng/ml and cells were infected on day 8 with the human – 1173 bp TNF promoter luciferase reporter adeno-
virus. On day 9 cells were stimulated for 5 hours with LPS at 500 ng/ml and luciferase activity was determined and normalized 
to protein content. Given is the average of 4 experiments. 100% represents 329560 +/- 373169 RLU in these experiments. * = 
p < 0.05 compared to 0/LPS. The hexagones denote NF-B binding sites in the human TNF promoter at -873, a complex site 
from -627 to -589 including a site at – 605, and a site at -104 relative to transcription start. B. Reduced NF-B activity in LPS 
tolerant dendritic cells. Day 7 dendritic cells were pre-cultured without and with LPS at 5 ng/ml and cells were infected on day 
8 with a luciferase reporter adenovirus driven by a tetramer of NF-B motifs. On day 9 cells were stimulated for 5 hours with 
LPS at 500 ng/ml and luciferase activity was determined and normalized to protein content. Given is the average of 3 experi-
ments. 100% represents 13803,67 +/- 2651,93 RLU in these experiments. * = p < 0.05 compared to 0/LPS. The hexagones 
denote NF-B binding sites.
Effect of LPS tolerance induction on levels of IRAK1 protein Figure 5
Effect of LPS tolerance induction on levels of IRAK1 
protein. Day 7 dendritic cells were cultured for additional 2 
days with LPS at 5 ng/ml and then washed and stimulated at 
500 ng LPS/ml. Lysates were prepared at 1 h and were sub-
jected to Western blotting for IRAK-1 (A) or SHIP (B). One 
representative of 4 experiments.
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Induction of LPS tolerance in dendritic cell cultures: effect on  IL-12 mRNA Figure 6
Induction of LPS tolerance in dendritic cell cultures: 
effect on IL-12 mRNA. Day 7 dendritic cells were cul-
tured for additional 2 days with LPS at 5 ng/ml and then 
washed and stimulated at 500 ng LPS/ml. Cells were lysed at 
6 hours and RNA was extracted, transcribed into cDNA and 
amplified by RT-PCR and data were normalized relative to 
levels of the house keeping gene alpha-Enolase. Given is the 
average of 3 experiments. * = p < 0.05 compared to 0/LPS.
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Induction of Pam3Cys tolerance in dendritic cells and effect on levels of IRAK1 protein Figure 7
Induction of Pam3Cys tolerance in dendritic cells and effect on levels of IRAK1 protein. Day 7 dendritic cells were 
cultured for additional 2 days with Pam3Cys at 1g/ml and then washed and stimulated at 10 g Pam3Cys/ml. A. Cells were 
lysed at 2 hours and RNA was extracted, transcribed into cDNA and amplified by RT-PCR and data were normalized relative 
to levels of the house keeping gene alpha-Enolase. Given is the average of 5 experiments. * = p < 0.05 compared to 0/LPS. B. 
Lysates were prepared at 1 h and were subjected to Western blotting for IRAK-1. One representative of 3 experiments. C. 
Lysates were prepared at 1 h and were subjected to Western blotting for IRAK-4. One representative of 3 experiments.
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Pam3Cys appeared much stronger in this system since
IRAK-1 had already completely disappeared after 1 h of
treatment with Pam3Cys and in cells treated with
Pam3Cys for 2 days no IRAK-1 protein was detectable (Fig.
7B). Hence, it appears that for both TLR4 and TLR2 lig-
ands the same mechanism of tolerance operate in human
DCs. While these data are highly suggestive of a role of
IRAK-1 in tolerance of human DCs, over-expression in tol-
erant cells of IRAK-1 using for instance adenoviral vectors
will be required to confirm this conclusion.
The downregulation of IRAK-1 did occur at the protein
level, since RT-PCR analysis did not demonstrate any sig-
nificant change in IRAK-1 transcript levels (data not
shown). An additional mechanism of tolerance is the
downregulation of TLR-4 such that signal transduction is
blocked at the receptor level as described by Nomura et al
[28]. We have addressed this point but were unable to
obtain detectable cell surface staining with anti-TLR4 in
the in-vitro generated DCs, probably due to a low number
of receptors on these cells. Analysis of TLR-4 mRNA dem-
onstrated that levels were unchanged in tolerance (data
not shown). Still, it is conceivable that in DCs tolerance in
response to different stimuli acts at multiple levels includ-
ing receptors expression, signal transduction and gene
expression.
When using different TLR-ligands cross-tolerance can be
observed and this has been shown by several groups [29-
33]. The study by Sato has clearly shown that cross-toler-
ance will occur when signalling pathways converge.
Hence, TLR2 and TLR4 ligands induce cross-tolerance
with respect to TNF via the shared MyD88 pathway and
TLR3 and TLR4 ligands do so with respect to IP-10 via the
shared TRIF pathway [33]. With respect to dendritic cells
a similar scenario can be expected but further studies are
needed to address this point.
IRAK-4 is another crucial kinase and adaptor, which inter-
acts with the TLR receptor complex and mediates activa-
tion of IRAK-1 and NF-B [34]. Defects of IRAK-4 can lead
to immunodeficiency with decreased cytokine production
leading to increased susceptibility to infection with pyo-
genic bacteria, like staphylococci and streptococci during
childhood [35-37]. We therefore have asked whether in
tolerant DCs, which do not activate NF-B and fail to pro-
duce cyokines, there may be an additional decrease in
expression of IRAK-4. Our data show, however, that this
protein is not altered in tolerant DC (Fig 7C).
In human macrophages induction of LPS tolerance has
been shown to lead to down-regulation of MHC Class II
molecules with subsequent reduction of activation of T
cells [38]. In the present study on DCs we could not dem-
onstrate such a decrease, in that naïve cells showed Class
II expression at 91.6 +/- 29.1 channels in flow cytometry
and LPS tolerant cells were at 83.8 +/- 25.6 channels. Sim-
ilarly there was no change in expression of MHC Class I in
Pam3Cys tolerant cells (data not shown). These data sug-
gest that with respect to MHC expression mechanisms of
TLR-mediated tolerance are different between macro-
phages and DCs. We do not know at this stage, whether
the tolerant DCs generated in this study will show a
reduced activation of antigen specific T cells. We assume,
however, that given the almost complete down-regulation
of the crucial cytokines TNF and IL-12 tolerance in DCs
will lead to inferior activation of TH1 lymphocytes and
lower expression of IFN by these cells. Such tolerant cells
may preferentially activate TH2 cells and non-polarized T
cells as described by Langenkamp et al. [39].
In this study we have focused on the expression of the TNF
gene but we could also demonstrate blockade of IL-12
gene expression in tolerant DCs. Since IL-12 is also gov-
erned by NF-B transcription factor [40,41] it is conceiva-
ble the molecular mechanism of ablation of IRAK-1 is
responsible for the blockade of IL-12, as well.
In the present report we have induced tolerance in mature
CD83+ dendritic cells, while others have looked at imma-
ture cells treated with LPS or TNF plus IL-1beta [6,39,42].
When looking at immature cells the analysis is compli-
cated by the problem that treatment with a given stimulus
will induce two processes, i.e. maturation and tolerance,
such that it is difficult to define whether down-regulation
of a given gene is due to maturation or to tolerance.
We have induced maturation with PGE2, which is used for
DC generation in many clinical trials and we have found
PGE2 induced cells to be highly informative for the study
of tolerance. While Kalinski et al have reported that such
cells show no IL-12 expression [43] we found a robust
expression of IL-12 mRNA. This difference may be
explained by the fact that Kalinski et al added PGE2 from
the start of culture, while we have added this compound
only for the final 2 of the 7 days of culture.
For the purpose of this study we have not used maturation
with LPS [44], TNF [45,46] or a combination of TNF and
IL-1 [42], since maturation with all of these stimuli may
induce a state of tolerance, such that we cannot study the
mechanisms of tolerance in response to LPS anymore.
In addition to tolerance via TLR-ligands the pro-inflam-
matory cytokine TNF has also been shown to induce tol-
erance in monocytic cells and here a mechanism of c/EBP
interference with NF-B phosphorylation was demon-
strated [47,48]. The dose of LPS used for pre-culture in the
present study (5 ng/ml) will induce TNF and this TNF
could contribute to tolerance via the c/EBP mediatedBMC Immunology 2008, 9:69 http://www.biomedcentral.com/1471-2172/9/69
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interference with NF-B. Such an additional mechanism
may come into play in settings where the depletion of
IRAK-1 is incomplete.
While the present work has been done on in-vitro gener-
ated human DCs it remains to be shown whether similar
mechanisms will operate in primary DCs isolated from
tissue. Such tolerance of primary dendritic cells after TLR-
ligation in settings of infection will likely contribute to a
reduced immune response, which may be detrimental but
could also be beneficial in that an over-reaction of the
immune system is avoided.
Conclusion
Our study provides the first data on molecular mecha-
nisms on tolerance in DCs. We show that TLR-ligands can
render DCs tolerant with respect to TNF gene expression
by a mechanism that likely involves blockade of signal
transduction at the level of IRAK-1.
Methods
Culture medium
Culture medium was RPMI 1640 plus non-essential
amino acids, L-glutamine, Penicillin, Streptomycin, oxala-
cetate, pyruvate and insulin http://www.monocytes.de.
This medium was passed through a U2000 column (Gam-
bro Medizin-Technik, Planegg-Martinsried, Germany) in
order to remove any inadvertently introduced LPS, and
this was followed by addition of 1% (v/v) of a pool of
human serum obtained from apparently healthy male
donors.
Cells and stimulation
Heparinised (10 U/ml) venous blood was obtained from
healthy volunteers after informed consent. The study was
approved by the ethics committee of the Ludwig-Maximil-
ians University Munich with the number 279/4. PBMC
were isolated by density gradient separation and were
seeded at 5 × 106 cells/ml in 2 ml volumes of medium in
6 well plates (# 3506 Costar, Bodenheim, Germany). After
incubation for 1 h non-adherent cells were removed and
fresh 2 ml medium containing GM-CSF (50 ng/ml, Leuk-
ine®, #1111180, Megapharm, St. Augustin, Germany) and
IL-13 (50 ng/ml, generously provided by IDM, Paris,
France) was added. After culture at 37°C for 5 days PGE2
(0.85 M, # PG-007, Biomol, Hamburg, Germany) was
added for another 2 days.
For induction of tolerance to LPS these day 7 DCs were
harvested and seeded at 1 × 106/ml in 2 ml volumes in 24-
well ultra low-attachment plates (# 3476, Costar) without
or with LPS (5 ng/ml, Salmonella abortus equi, kindly
provided by Dr. Chris Galanos, Freiburg, Germany, [49].
The dose of 5 ng/was chosen to be well in the plateau of
the titration curve and at the same time in the lower range
in order to allow for sensitive detection of any decrease
induced by the secondary stimulation. After 2 days cells
were stimulated without or with LPS at 500 ng/ml.
For induction of tolerance to Pam3Cys day 7 DCs were
pre-treated with or without the compound (#L2000, EMC
microcollections, Tuebingen, Germany) at 1g/ml in 24-
well ultra low attachment plates (#3476, Costar) at 1 ×
106 cells/ml for two days followed by stimulation with or
without Pam3Cys at 10 g/ml.
Flow cytometry
Cell surface staining of dendritic cells was done by incu-
bation of the cells for 30 min on ice with CD1a-FITC
(#555806), CD83-PE (#556855) and CD209-FITC
(#551264) or the respective isotype controls (all from BD
Pharmingen, Heidelberg, Germany). Also, we used anti-
HLA DR- PC5 (PN IM2695, Beckman-Coulter, Krefeld,
Germany).
At least 1 × 105 cells were then analysed on an EPICS-XL
flow cytometer (Beckman-Coulter) and signals were
expressed as specific mean fluorescence intensity, i.e.
mean fluorescence intensity of the CD or anti-MHC anti-
body minus mean fluorescence intensity of the isotype
control.
Isolation of CD83+ cells
Day 7 dendritic cells were reacted with anti-CD83-Phyco-
erythrin (#556855, BD Pharmingen) followed by
microbead-conjugated anti-PE antibody (#130-048-80,
Miltenyi-Biotech, Bergisch-Gladbach, Germany). Cells
were then purified using a paramagnetic LS column
according to manufacturer's instructions (#130-042-401,
Miltenyi).
RT-PCR
Cells (2 × 104) were lysed in 200 l TRI-Reagent (#T-9424,
Sigma, Deisenhofen, Germany) and incubated for 5 min
at RT. To this we added 3 l tRNA (5,67 g/l) plus 40 l
Chloroform and RNA was isolated from the water phase
as per manufacturer's instruction. The mRNA was reverse
transcribed using MuLV RT (N8080018, Applera, Darm-
stadt, Germany). The quantitative PCR was performed
using the LightCycler® system (Roche Diagnostics, Man-
nheim, Germany) according to the manufacturer's
instructions by using the primer pairs as noted below. In
brief, 3 l of cDNA was used for amplification in the SYBR
Green format using the LightCycler – FastStart DNA Mas-
ter SYBR Green I kit from Roche (#2 239 264, Mannheim,
Germany) in a total volume of 20 l per capillary. The fol-
lowing primer pairs were used: 5' -Enolase: 5' GTT AGC
AAG AAA CTG AAC GTC ACA 3'; 3' -Enolase: 5' TGA
AGG ACT TGT ACA GGT CAG 3'; 5' TNF : 5' CAG AGG
GAA GAG TTC CCC AG 3'; 3' TNF : 5' CCT TGG TCTBMC Immunology 2008, 9:69 http://www.biomedcentral.com/1471-2172/9/69
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GGT AGG AGA CG 3'; 5' IL-12p40: 5' CCA AGA ACT TGC
AGC TGA AG 3'; 3' IL-12p40: 5' CTG TGT TGC CTT ATC
TGG GT 3'.
Fluorescent signals generated during this informative log-
linear phase were used to calculate the relative amount of
template DNA. Signals for TNF were normalised against
the -Enolase house keeping gene using the LightCycler®
Relative Quantification Software (Version 1.0, Roche).
Reporter gene analysis
Day 7 dendritic cells were seeded at 1 × 105 cells in 200 l
MM6-Medium + 1% HS in 96-well low attachment-plates
(Costar) and they were either left untreated or treated with
LPS at 5 ng/ml. On day 8 cells were infected with adeno-
virus 10:1 MOI using a TNF promoter luciferase reporter
gene virus carrying the -1173 TNF promoter in front of the
luciferase reporter gene and downstream the 3' UTR, as
given in [9] or a 4 × NF-B luciferase reporter gene virus
[50]. On day 9 cells were stimulated without or with LPS
at 500 ng/ml for 5 hs followed by assay of luciferase activ-
ity. For this cells were resuspended in 250 l buffer
(#E1501, Luciferase Assay System Promega, Mannheim)
and cells were disrupted by 3 freeze thaw cycles. 20 l aliq-
uots were then analysed in a Luminometer (Sirius,
Berthold Detection Systems, Pforzheim, Germany).
TNF ELISA
For determination of TNF protein DCs were pre-incubated
for 2d in the presence or absence of 5 ng/ml LPS. Cultures
were then stimulated without or with LPS at 500 ng/ml
and supernatants were harvested after 6 h. Cell free super-
natants were then tested for protein concentration with
commercial ELISA kit systems for TNF (PeliKine-com-
pact™, #M1923, CLB via HISS Diagnostics, Freiburg, Ger-
many) according to the manufacturer's instructions.
Sensitivity of the ELISA kit was 1 pg protein/ml.
Western blotting
Cell lysates were obtained by resuspending the cell pellet
in 4 volumes of buffer A (10 mM HEPES pH 7,9, 10 mM
KCl, 1,5 mM MgCl2 plus 2 mM DTT, Aprotinin at 10 g/
ml, 0,1 M PMSF) and after sonication nuclei were pelleted
and the supernatant (cytosol) was obtained and admixed
with an equal volume of 60% glycerol to be stored at -
80°C. Protein concentrations were determined using
Bradford reagent in the NanoDrop® ND-1000 Spectropho-
tometer (NanoDrop Technologies, Wilmington, USA)
using bovine serum albumin as a standard. Lysates were
separated using pre-cast NuPage™ Bis-Tris-Gels (4–12%,
Invitrogen) using a NOVEX EI9001-XCELL™ II Mini Cell.
Proteins were then blotted onto nitrocellulose-mem-
branes (Hybond™ECL™). Blots were blocked with dry
milk powder and then reacted with primary antibodies
rabbit anti-human actin, (#A-2066, Sigma-Aldrich),
mouse anti-human IRAK-1 (#sc-5287, Santa Cruz Bio-
technology), rabbit anti-human IRAK-2 (#905-264, Bio-
mol), rabbit anti-human IRAK-4 (#905-266, Biomol) or
mouse anti-human SHIP1 (#sc-8425, Santa Cruz Biotech-
nology). This was followed by incubation with the appro-
priate peroxidase-conjugated secondary reagent (anti-
mouse IgG, #A-7282 Sigma-Aldrich or anti-rabbit IgG, A-
0545 Sigma-Aldrich). Membranes were then reacted with
the ECL™ Western Blotting Detection Reagent
(#RPN2106, Amersham Biosciences, Freiburg) and
exposed to Hyperfilm™ECL (#RPN3103, 18 × 24 cm,
Amersham). Numeric values were obtained by densitom-
etry analysis of the exposed films. Values were corrected
with reference to the actin level and data were expressed as
% of the signal obtained in untreated cells, which was set
at 100%.
Statistical analysis
Statistical analysis was performed using Students' T-test.
Abbreviations
DC: dendritic cell; TLR: toll like receptor; LPS: lipopoly-
saccharide; IRAK: interleukin-1 receptor associated
kinases; TNF: tumour necrosis factor.
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